Strategic report Chairmans statement I am pleased to report our 2017 annual results with record revenue for theyear ended 30th June 2017 of536.8m compared to a restated 427.2m for last year.
TheGroups adjusted profit before tax for the year was 109.1m.
Sir David McMurtry Chairman and Chief Executive 2017 performance Restated 2017 2016 Change Revenue m 536.8 427.2 26% Adjusted profit before tax m 109.1 87.5 25% Adjusted earnings per share pence 132.4 100.4 32% Dividend per share pence 52.0 48.0 8% Statutory profit before tax m 117.1 61.7 90% Statutory earnings per share pence 141.3 71.8 97% D New XM-60 multi-axis calibrator.
04 Renishaw plc Annual report and accounts 2017 Strategic report Governance Financial statements Shareholder information Performance overview Revenue I am pleased to report our 2017 annual We achieved record turnover with results.
We achieved a record turnover revenue for the year ended 30th June of 536.8m with an underlying revenue 2017 of 536.8m, compared with growth of 14% at constant exchange a restated 427.2m for last year, an rates.
We report an adjusted profit increase of 26%.
There was underlying before tax of 109.1m and a statutory revenue growth of 14% with the profit before tax of 117.1m, an balance arising from exchange rate increase of 25% on an adjusted basis.
movements compared to the prior year.
Our total shareholder return during the The geographical analysis of revenue is year was 67%, ranking Renishaw in as follows: the top 25 in both the FTSE 250 and Restated Constant fx FTSE 350.
2017 2016 Change change m m % % Renishaw is a long-term business Far East 248.9 193.3 29% 14% and we remain committed to strategic investments and R&D.
In addition, Europe 129.9 110.3 18% 12% over the past year, we have focused Americas 113.6 88.0 29% 13% on underperforming business areas UK 27.6 22.8 21% 21% resulting in our discontinuing the activities of Renishaw Diagnostics Other regions 16.8 12.8 31% 30% Limited and the spatial measurement Total group revenue 536.8 427.2 26% 14% business.
In spite of the potential headwinds brought about by the Profit and earnings per share uncertainty of Brexit, we remain During the year, it was established the basis by which the Board evaluates confident of future growth due that certain foreign currency forward the Groups performance as it better to our innovative product base, contracts used as hedging instruments represents the underlying trading of the extensive global sales and marketing for future incoming currency cash flows Group.
The consolidated net assets presence, and relevance to highdid not qualify for hedge accounting.
and cash balances were not impacted value manufacturing.
This has resulted in the prior year profit by the prior year adjustment and the before tax being restated and as a future cash flows remain unchanged.
consequence the Board has introduced The Groups adjusted profit before an alternative performance measure, tax for the year was 109.1m, an adjusted profit before tax, to report increase of 25% compared to 87.5m the profitability on the basis that all last year.
Adjusted earnings per share forward contracts are accounted for as on continuing activities were 132.4p effective hedges.
This measure will be compared to 100.4p last year.
Financial highlights 1 Adjusted profit Statutory profit Revenue m before tax m before tax m 536.8m 109.1m 117.1m 1 Adjusted earnings Statutory earnings Dividend per share pershare pence pershare pence pence 141.3p 132.4p 52.0p 1 note 24, Alternative performance measures, defines how adjusted profit before tax and adjusted earnings per share are calculated.
Our additive manufacturing AM product line introduced the continued Adjusted operating profit for our RenAM 500M machine and opened an metrology business was 115.9m additional two AM solutions centres in Statutory profit before tax for the year 2016 restated: 90.0m.
was 117.1m compared to a restated We have continued to invest in 61.7m last year.
Statutory earnings Healthcare research and development, with total per share on continuing activities were engineering costs in this business Revenue from our healthcare business 141.3p compared to 71.8p last year.
segment of 68.8m before net for the year was 33.4m, an increase This years tax charge on continuing capitalised development costs and the of 18% over the 28.4m last year.
operations amounts to 14.3m 2016 R&D tax credit compared to a restated We experienced growth in all our restated: 10.0m representing a 2016 of 60.9m, with a number of new product lines.
tax rate of 12.2% 2016 restated: product launches during the year.
The tax rate has benefited In our CMM product line, we investment in research and from the continued phasing in of the launched a new, improved surface development, with total engineering patent box tax regime and a reduction finish measurement probe for use costs in this business segment in the UK tax rate applied when with our REVO 5-axis measurement of 9.2m before net capitalised calculating certain deferred tax assets system.
The laser calibration product development costs and the R&D tax and liabilities.
line launched the XM-60 multi-axis credit compared to a restated 2016 of calibrator.
Metrology tool market, it is a highly accurate Revenue from our metrology business In our spectroscopy product line, we laser system used to capture multiple for the year was 503.4m compared introduced the RA802 pharmaceutical machine errors in a single set-up.
In our with a restated 398.9m last year.
analyser, designed exclusively for the encoder product line, we launched pharmaceutical industry, enabling users We have experienced revenue growth the VIONiC series, a new range of to formulate tablets more efficiently in all product lines and territories.
ultra-high accuracy, super-compact by speeding up the analysis of tablet The geographical analysis of revenue all-in-one digital incremental encoders.
isset out below: Restated The neurological product line continued 2017 2016 Change to make sales of our stereotactic robot m m % and associated neuroinspire planning Far East 237.9 185.6 28% software, with further sales in the UK, USA and Canada.
Europe 121.5 101.3 20% The medical dental product line has Americas 106.9 83.3 28% experienced good growth resulting UK 23.2 18.1 29% from a continued focus on sales of additive manufacturing technologies Other regions 13.9 10.6 31% into the healthcare market.
Total group revenue 503.4 398.9 26% D SFP2 surface measurement probe inspecting a crankshaft.
D RA802 pharmaceutical analyser is a compact benchtop Raman imaging D Demonstration area at the new headquarters of Renishaw, Inc. system, designed exclusively for the pharmaceutical industry.
06 Renishaw plc Annual report and accounts 2017 Strategic report Governance Financial statements Shareholder information There was an adjusted operating loss outstanding at the end of the current Continued investment for of 7.2m, compared with a restated year at 73 days 2016: 70 days.
long-term growth loss of 3.1m last year.
We remain The Group continues its strategy to Net cash balances at 30th June 2017 focused on moving this business invest for the long term, expanding were 51.9m, compared with 21.3m sector into profit, where we have our global marketing and distribution at 30th June 2016.
Additionally, there implemented a number of initiatives infrastructure, along with increasing is an escrow account of 12.9m and are restructuring the neurological manufacturing capacity and 2016: 15.3m relating to the provision and medical dental businesses.
of security to the UK defined benefit This year saw the completion of pension scheme.
Discontinued activities our new USA headquarters near As reported in our October 2016 Directors and employees Chicago and the sale of the previous trading update, the Board decided to Now that Will Lee has settled into his premises.
New facilities have also discontinue operations at Renishaw role as Group Sales and Marketing been completed in Detroit USA Diagnostics Limited RDL, resulting Director since his appointment earlier in with expansion and refurbishment in in the closure of the business.
the year, he will take over responsibility Spain, Sweden, Hungary, Germany Subsequently, certain assets of the from John Deer for chairing the and France.
We also converted our business have been sold.
International Sales & Marketing Board representative office in Turkey into a The RDL business has been accounted from the start of the new financial year.
trading subsidiary to facilitate solution for as a discontinued activity, with selling in the territory.
The directors would like to express comparative figures for the previous their thanks to all employees for their Our workforce at the end of June 2017 year being restated accordingly.
invaluable support and contribution was 4,530, an increase of 244 in the The loss after tax of 3.3m accounted during the year.
year, of which 91 were apprentices for as a discontinued activity comprises and graduates taken on as part of our the running costs for RDL, including Investor communications on-going commitment to train and cessation costs and impairment write Our fourth investor day was held develop skilled resource for the Group offs for assets and goodwill, less on 11th May 2017, for existing and in the future.
The loss after tax for potential new investors.
This event the prior year was 2.5m.
Capital expenditure on property, involves presentations on group plant and equipment for the year was strategy, business segments and In June 2017, after an extensive review 42.6m, of which 24.2m was spent product lines as well as tours of the spatial measurement business, on property and 18.4m on plant covering the Groups activities and an the Board decided to discontinue and equipment.
opportunity to meet the Board and this line of business.
There was also a goodwill impairment charge of 6.7m Working capital Q&A session with the Board.
The event and provisions for the cessation of Group inventory decreased from was very well attended, and provided the trade, there was a net loss in 95.0m at the start of the year shareholders with another opportunity, this business for the year of 10.6m to 87.7m.
We continue to focus in addition to the AGM, half-year and 2016: 1.5m.
on working capital management full-year webcasts, to learn more about whilst remaining committed to our Renishaws business and strategy.
policy of holding sufficient finished inventory to ensure customer delivery performance, given our short order book of approximately five weeks.
Trade debtors increased from 114.9m to 137.5m, with debtor days D Carwyn Jones, First Minister of Wales, opened the Healthcare Centre of Excellence at Miskin.
D Official opening of Renishaw Taiwan Inc. s new office performed by senior Renishaw managers, government officials and representatives from Taiwanese industry.
D VIONiC digital all-in-one incremental encoder.
07 Strategic report Chairmans statement continued Outlook Previous year figures have been restated for the following: The Group is in a strong financial 1.
The results of Renishaw Diagnostics Limited and the spatial measurement position and continues to invest in business have been excluded, as these businesses have been reclassified as the development of new products discontinued activities.
and applications, along with targeted investment in production, and sales 2.
The R&D tax credit, previously accounted for within the income tax expense line, has been reclassified to cost of sales, thereby showing it as part of the profit before tax.
and marketing facilities around the This reclassification increased the profit before tax by 2.4m for the year ended 30th world.
We have experienced strong June 2016. growth in 2017 and whilst noting ongoing uncertainty surrounding Brexit 3.
It has been established that certain foreign currency forward contracts used as and currency exchange rate volatility, hedging instruments for future incoming currency cash flows did not qualify for your directors remain confident in the hedge accounting as they did not meet the hedge effectiveness criteria set out in the International Accounting Standard IAS 39 Financial Instruments: Recognition long-term prospects for the Group and and Measurement.
To ensure technical compliance with this standard it has been at this early stage in the year anticipate necessary to restate the 2016 financial statements resulting in a 25.8m reduction to growth in both revenue and profits in the profit before tax for that year and a corresponding increase in other comprehensive the current financial year.
The consolidated net assets and cash balances were not impacted by the prior year adjustment and the future cash flows remain unchanged.
Dividend A final dividend of 39.5p net per share Alternative performance measures will be paid on 25th October 2017, to shareholders on the register on Alternative performance measures are Revenue at constant exchange rates, Adjusted profit before tax, Adjusted earnings per share and Adjusted operating profit.
22nd September 2017, giving a total dividend of 52.0p for the year, an Revenue at constant exchange rates is defined as revenue recalculated using the same increase of 8.3% over last years 48.0p.
rates as were applicable to the previous year and excluding forward contract gains and losses.
Revenue at constant exchange rates 2017 2016 m m Sir David McMurtry Statutory revenue as reported 536.8 427.2 Chairman and Chief Executive Adjustment for exchange rate movements and forward 27th July 2017 contract gains and losses 52.0 2.6 Revenue at constant exchange rates 484.8 424.6 Adjusted profit before tax, Adjusted earnings per share and Adjusted operating profit are after excluding gains and losses in fair value from forward currency contracts which did not qualify for hedge accounting.
The amounts shown below as reported in revenue represent the amount by which revenue would change had all the derivatives qualified as eligible for hedge accounting.
Adjusted profit before tax 2017 2016 m m Statutory profit before tax 117.1 61.7 Fair value gains and losses on financial instruments not effective for cash flow hedging: - reported within revenue 11.6 2.4 - reported as losses in the fair value of financial instruments 3.6 23.4 Adjusted profit before tax 109.1 87.5 Adjusted earnings per share and adjusted operating profit are calculated using the same adjustments.
The Board have used these alternative performance measures as they consider them to be a more relevant and reliable assessment of the performance of the group see note 24.
08 Renishaw plc Annual report and accounts 2017
